Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
James W. B. Elsey, Vivi Anna F. Wuestman & Anouk Fieten. (2023) User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample. Drugs: Education, Prevention and Policy 0:0, pages 1-13.
Read now
Read now
Jason B. Luoma, Brian Pilecki, Alan K. Davis & Sarah M. Smith. (2023) Predictors of attitudes toward psychedelics among psychologists in the USA. Drugs: Education, Prevention and Policy 30:6, pages 543-549.
Read now
Read now
Julie J. Exline, William A. Schutt, Kathleen C. Pait & Joshua A. Wilt. (2023) Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use. The International Journal for the Psychology of Religion 33:4, pages 361-379.
Read now
Read now
Petter Johnstad. (2023) Entheogenic Spirituality: Characteristics of Spiritually Motivated Psychedelics Use. The International Journal for the Psychology of Religion 33:4, pages 380-396.
Read now
Read now
Kevin O. St. Arnaud. (2023) Toward a positive psychology of psychoactive drug use. Drugs: Education, Prevention and Policy 30:1, pages 81-94.
Read now
Read now
Kevin O. St. Arnaud & Donald Sharpe. (2023) Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users. Journal of Psychoactive Drugs 55:1, pages 30-39.
Read now
Read now
Ciarán Martin Fitzpatrick, Brian T. Anderson, Gabrielle Agin-Liebes & Joseph Guydish. (2022) Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms. Journal of Psychoactive Drugs 54:4, pages 324-327.
Read now
Read now
Alan K. Davis, Gabrielle Agin-Liebes, Megan España, Brian Pilecki & Jason Luoma. (2022) Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs 54:4, pages 309-318.
Read now
Read now
Alan K. Davis & Harold Rosenberg. (2015) Application of the Passionate Attachment Model to Recreational Use of MDMA/Ecstasy. Journal of Psychoactive Drugs 47:1, pages 24-29.
Read now
Read now
Brittany Vasae Burdick & Bryon Adinoff. (2013) A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. The American Journal of Drug and Alcohol Abuse 39:5, pages 291-297.
Read now
Read now
Articles from other publishers (44)
Marie Crowe, Jenni Manuel, Dave Carlyle & Cameron Lacey. (2023) Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?. International Journal of Mental Health Nursing 32:6, pages 1766-1772.
Crossref
Crossref
Jules Evans, Oliver C. Robinson, Eirini Ketzitzidou Argyri, Shayam Suseelan, Ashleigh Murphy-Beiner, Rosalind McAlpine, David Luke, Katrina Michelle & Ed Prideaux. (2023) Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLOS ONE 18:10, pages e0293349.
Crossref
Crossref
Brian Claude Macallan. (2023) Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences. Religions 14:10, pages 1312.
Crossref
Crossref
Rebecka Bremler, Nancy Katati, Parvinder Shergill, David Erritzoe & Robin L. Carhart-Harris. (2023) Case analysis of long-term negative psychological responses to psychedelics. Scientific Reports 13:1.
Crossref
Crossref
NM Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang, Yiqun Sun, Brenda Nava, Luke Sampiere, Akhila Yerubandi & Joshua Caballero. (2023) Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin. Cureus.
Crossref
Crossref
Pravesh Sharma, Quang Anh Nguyen, Sadie J Matthews, Erin Carpenter, Douglas B Mathews, Christi A Patten & Christopher J Hammond. (2023) Psilocybin history, action and reaction: A narrative clinical review. Journal of Psychopharmacology 37:9, pages 849-865.
Crossref
Crossref
Kevin O. St. Arnaud & Donald Sharpe. (2022) Opening to Awe: Psychedelic-Assisted Self-Transcendence and Positive Adult Development. Journal of Adult Development 30:3, pages 305-319.
Crossref
Crossref
Emma I Kopra, Jason A Ferris, Adam R Winstock, Kim PC Kuypers, Allan H Young & James J Rucker. (2023) Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Journal of Psychopharmacology 37:7, pages 733-748.
Crossref
Crossref
Irene Li, Rodney Fong, Molly Hagen & Burton Tabaac. (2023) Medical student attitudes and perceptions of psychedelic-assisted therapies. Frontiers in Psychiatry 14.
Crossref
Crossref
Rebecca S. Ryan, Alex Copello & Andrew P. Fox. (2023) Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. BMC Psychiatry 23:1.
Crossref
Crossref
Jules Evans, Oliver Robinson, Eirini Ketzitzidou-Argyri, Shayam Suseelan, Ashleigh Murphy-Beiner & Rosalind McAlpine. (2023) Extended Difficulties Following the Use of Psychedelic Drugs: A Mixed Methods Study. SSRN Electronic Journal.
Crossref
Crossref
Madelene Palmer & Olivia M. Maynard. (2022) Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduction Journal 19:1.
Crossref
Crossref
Haley Maria Dourron, Camilla Strauss & Peter S. Hendricks. (2022) Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacological Reviews 74:4, pages 984-1029.
Crossref
Crossref
Adam Levin, Paul B Nagib, Selina Deiparine, Thomas Gao, Justin Mitchell & Alan K Davis. (2022) Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. International Journal of Drug Policy 108, pages 103816.
Crossref
Crossref
Pavla Chomynová, Rita Kočárová, Filip Kňažek, Michaela Plevková, Barbora Bláhová, Karel Valeš & Viktor Mravčík. (2022) Use of psychedelics in the Czech Republic: results of recent population surveys. Central European Journal of Public Health 30:3, pages 144-153.
Crossref
Crossref
Paweł Orłowski, Anastasia Ruban, Jan Szczypiński, Justyna Hobot, Maksymilian Bielecki & Michał Bola. (2022) Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. Journal of Psychopharmacology 36:8, pages 987-1000.
Crossref
Crossref
Emma I Kopra, Jason A Ferris, Adam R Winstock, Allan H Young & James J Rucker. (2022) Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Journal of Psychopharmacology 36:8, pages 965-973.
Crossref
Crossref
Emma I Kopra, Jason A Ferris, James J Rucker, Benjamin McClure, Allan H Young, Caroline S Copeland & Adam R Winstock. (2022) Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). Journal of Psychopharmacology, pages 026988112210996.
Crossref
Crossref
Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill & David J Nutt. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 36:3, pages 258-272.
Crossref
Crossref
Anna O Ermakova, Fiona Dunbar, James Rucker & Matthew W Johnson. (2021) A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology 36:3, pages 273-294.
Crossref
Crossref
Joseph M Peill, Katie E Trinci, Hannes Kettner, Lea J Mertens, Leor Roseman, Christopher Timmermann, Fernando E Rosas, Taylor Lyons & Robin L Carhart-Harris. (2022) Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology 36:1, pages 31-45.
Crossref
Crossref
David E. Gard, Mollie M. Pleet, Ellen R. Bradley, Andrew D. Penn, Matthew L. Gallenstein, Lauren S. Riley, Meghan DellaCrosse, Emily M. Garfinkle, Erin E. Michalak & Joshua D. Woolley. (2021) Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. Journal of Affective Disorders Reports 6, pages 100240.
Crossref
Crossref
Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams & David J Castle. (2019) Psilocybin-assisted therapy for depression: How do we advance the field?. Australian & New Zealand Journal of Psychiatry 54:3, pages 225-231.
Crossref
Crossref
Zuzana Postránecká, Čestmír Vejmola & Filip Tylš. (2019) Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?. Journal of Psychedelic Studies 3:1, pages 19-31.
Crossref
Crossref
Edward James, Thomas L Robertshaw, Michael J Pascoe, Fiona M Chapman, Andrew D Westwell & Andrew P Smith. (2019) Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs. Drug Science, Policy and Law 5, pages 205032451987612.
Crossref
Crossref
Lindsay P. Cameron & David E. Olson. (2018)
Dark Classics in Chemical Neuroscience:
N
,
N
-Dimethyltryptamine (DMT)
. ACS Chemical Neuroscience 9:10, pages 2344-2357.
Crossref
Crossref
David Dolan, Henrik J. Jensen, Pedro A. M. Mediano, Miguel Molina-Solana, Hardik Rajpal, Fernando Rosas & John A. Sloboda. (2018) The Improvisational State of Mind: A Multidisciplinary Study of an Improvisatory Approach to Classical Music Repertoire Performance. Frontiers in Psychology 9.
Crossref
Crossref
Link R. Swanson. (2018) Unifying Theories of Psychedelic Drug Effects. Frontiers in Pharmacology 9.
Crossref
Crossref
Edward James, Thomas L Robertshaw, Andrew D Westwell & Andrew P Smith. (2018) Pharmacies as potential providers of harm reduction services: A preliminary online survey. Drug Science, Policy and Law 4, pages 205032451876744.
Crossref
Crossref
Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery & Fabrizio Schifano. (2017) The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. Frontiers in Psychiatry 8.
Crossref
Crossref
Jared I. Wildberger, Cassandra N. John & Robert M. Hallock. (2017) Perceptions of the medicinal value of hallucinogenic drugs among college students. Journal of Psychedelic Studies 1:2, pages 50-54.
Crossref
Crossref
Robin L Carhart-Harris & Guy M Goodwin. (2017) The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology 42:11, pages 2105-2113.
Crossref
Crossref
Ling-Yi Feng, Altansuvd Battulga, Eunyoung Han, Heesun Chung & Jih-Heng Li. (2017) New psychoactive substances of natural origin: A brief review. Journal of Food and Drug Analysis 25:3, pages 461-471.
Crossref
Crossref
Alan K Davis & Harold Rosenberg. (2017) Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom. Drug Science, Policy and Law 3, pages 205032451771106.
Crossref
Crossref
James JH Rucker, Luke A Jelen, Sarah Flynn, Kyle D Frowde & Allan H Young. (2016) Psychedelics in the treatment of unipolar mood disorders: a systematic review. Journal of Psychopharmacology 30:12, pages 1220-1229.
Crossref
Crossref
Jennifer Lyke. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
866
874
.
Mitchell G. Spring, Rory D. Ostrow & Robert M. Hallock. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
794
800
.
Michael P. Bogenschutz & Stephen Ross. 2018. Behavioral Neurobiology of Psychedelic Drugs. Behavioral Neurobiology of Psychedelic Drugs
361
391
.
Petter Grahl Johnstad. (2017) User perceptions of mental health consequences of hallucinogen use in self-identified spiritual contexts. Nordic Studies on Alcohol and Drugs 32:6, pages 545-562.
Crossref
Crossref
Dirk W. Lachenmeier & Jürgen Rehm. (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports 5:1.
Crossref
Crossref
Ruud P.W. Litjens, Tibor M. Brunt, Gerard-Jan Alderliefste & Remco H.S. Westerink. (2014) Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology 24:8, pages 1309-1323.
Crossref
Crossref
Emily L. B. Lykins. 2014. Religion and Spirituality Across Cultures. Religion and Spirituality Across Cultures
203
225
.
RL Carhart-Harris, S Brugger, DJ Nutt & JM Stone. (2013) Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of Psychopharmacology 27:9, pages 771-778.
Crossref
Crossref
Celia JA Morgan, Louise A Noronha, Mark Muetzelfeldt, Amanda Feilding & H Valerie Curran. (2013) Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. Journal of Psychopharmacology 27:6, pages 497-506.
Crossref
Crossref